FibroGen enters ATM equity offering agreement for up to $30M with BofA Securities

KYNTRA BIO, INC.

May sell up to $30M of common stock from time to time through BofA as sales agent.
BofA will receive a commission of up to 3.0% of gross sales proceeds.
Company is not obligated to sell any shares; offering may terminate upon sale of all shares or by agreement.
Shares sold under effective shelf registration (333-280597) and prospectus supplement dated Feb 24, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.